Keita Tamura

Keita Tamura

Auto-generated profile, based on publicly available information

Keita Tamura

Department of Urology Hamamatsu University School of Medicine Shizuoka Japan

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2022 in International Journal of Urology
Verified
Journal Article
Closed access
KWKyohei Watanabe
Kyohei Watanabe
AOAtsushi Otsuka
Atsushi Otsuka
ASAsuka Sano
Asuka Sano
RSRyo Sato
Ryo Sato
YMYuto Matsushita
Yuto Matsushita
HMHideaki Miyake
Hideaki Miyake

1 January 2020 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
KTKeita Tamura
Keita Tamura
YMYuto Matsushita
Yuto Matsushita
HWHiromitsu Watanabe
Hiromitsu Watanabe
DMDaisuke Motoyama
Daisuke Motoyama
TIToshiki Ito
Toshiki Ito
HMHideaki Miyake
Hideaki Miyake

22 January 2021 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Closed access
KTKeita Tamura
Keita Tamura
TOTakahiro Osawa
Takahiro Osawa
ATArio Takeuchi
Ario Takeuchi
KMKeita Minami
Keita Minami
YNYasutomo Nakai
Yasutomo Nakai
JGJapanese Urological Oncology Group
Japanese Urological Oncology Group
Purpose: To externally validate the utility of the albumin, C-reactive protein and lactate dehydrogenase model to predict the overall survival of previously treated metastatic renal cell carcinoma patients. Patients and methods: The ability of the albumin, C-reactive protein and lactate dehydrogenase model to predict overall survival was validated and compared with those of other prognostication models using data from 421 metastatic renal cell carcinoma patients receiving second-line axitinib therapy at 36 hospitals belonging to the Japan Urologic Oncology Group. Results: The following factors in this cohort were independently associated with poor overall survival in a multivariate analysis: a low Karnofsky performance status, 50%. The superiority of the albumin, C-reactive protein and lactate dehydrogenase model to the Memorial Sloan Kettering Cancer Center and International Metastatic Renal Cell Carcinoma Database Consortium models, but not the Japan Urologic Oncology Group model, was demonstrated by multiple statistical analyses. Conclusions: The utility of the albumin, C-reactive protein and lactate dehydrogenase model as a simple and objective prognostication tool was successfully validated using data from 421 metastatic renal cell carcinoma patients receiving second-line axitinib.

1 November 2021 in Journal of Endourology
Verified
Journal Article
Closed access
TIToshiki Ito
Toshiki Ito
KWKyohei Watanabe
Kyohei Watanabe
YMYuto Matsushita
Yuto Matsushita
HWHiromitsu Watanabe
Hiromitsu Watanabe
KTKeita Tamura
Keita Tamura
HMHideaki Miyake
Hideaki Miyake
Introduction: MRI has helped clarify the relationship between pelvic anatomical structures and functional outcomes after robot-assisted radical prostatectomy (RARP). The objective of this study was to assess the impact of the bladder neck angle (BNA) measured by postoperative MRI on midterm recovery of urinary continence (UC) in patients undergoing RARP. Patients and Methods: This study retrospectively included 200 consecutive patients with prostate cancer who were treated by RARP and received MRI 3 months after RARP. Based on postoperative MRI, the BNA was measured as the angle between the anterior and posterior bladder walls. The midterm recovery of UC was defined as the use of either no pad or an occasional security pad at 6 months after RARP. Results: One hundred forty-four of the 200 patients (72.0%) achieved midterm recovery of UC and the median BNA was 70°. There were no significant differences in several parameters, including age, body mass index, total prostate volume, preservation of the neurovascular bundle, and postoperative membranous urethral length (MUL), between patients with BNA ≥70° and <70°. Of these parameters, only the BNA and postoperative MUL were independently associated with the midterm recovery of UC. The optimal cutoff points of the BNA and MUL (65° and 9 mm, respectively) were calculated by the receiver operating characteristics curve, and a scoring model for the prediction of midterm recovery of UC was developed according to the logistic regression analysis. This scoring model was demonstrated to be satisfactorily calibrated ( p for Hosmer–Lemeshow test = 0.49) and provide good discrimination (area under the curve: 0.723; p < 0.001). Conclusions: These findings suggest that midterm recovery of UC after RARP is favorably affected by the large BNA and long postoperative MUL, and our scoring model can be used as a reliable tool for predicting the midterm continence status after RARP.

17 February 2022 in International Journal of Urology
Verified
Journal Article
Closed access
PDF file
KTKeita Tamura
Keita Tamura
YMYuto Matsushita
Yuto Matsushita
HWHiromitsu Watanabe
Hiromitsu Watanabe
DMDaisuke Motoyama
Daisuke Motoyama
TIToshiki Ito
Toshiki Ito
HMHideaki Miyake
Hideaki Miyake

19 August 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DMDaisuke Motoyama
Daisuke Motoyama
KWKyohei Watanabe
Kyohei Watanabe
YMYuto Matsushita
Yuto Matsushita
HWHiromitsu Watanabe
Hiromitsu Watanabe
KTKeita Tamura
Keita Tamura
TITeruo Inamoto
Teruo Inamoto
Background/Objectives: This study aimed to evaluate and compare the perioperative outcomes of robot-assisted partial nephrectomy (RAPN) for complex renal tumors performed using the novel Japanese Hinotori Surgical Robot System (HSRS) and the established Da Vinci Surgical System (DVSS). Methods: Of 484 consecutive patients who underwent RAPN at our institution, 126 with complex renal tumors were included in the DVSS group, and 48 such patients were included in the HSRS group. Complex tumors in this series were defined by the presence of at least one of the following factors: cT1b, completely endophytic, hilar, cystic, or ipsilateral multiple tumors. Results: Following 1:2 propensity score matching, 74 and 37 patients were included in the DVSS and HSRS groups, respectively. Post-matching, most covariates’ absolute standardized mean difference (SMD) was less than 0.1, indicating effective baseline imbalance correction. All RAPN procedures using HSRS were completed without conversion to open surgery, nephrectomy, or Clavien–Dindo ≥3 postoperative complications. No significant differences in major perioperative outcomes were observed between DVSS and HSRS, including operative time (178 vs. 186 min), console time (115 vs. 115 min; encompassing cockpit time for HSRS), warm ischemia time (15 vs. 15 min), and estimated blood loss (51 vs. 30 mL). Positive surgical margin rates (DVSS 1.4% vs. HSRS 5.4%) and Trifecta achievement rates (94.6% vs. 91.9%) were also comparable, with no significant differences. Conclusions: These findings suggest that, even in patients with complex renal tumors, RAPN performed using the HSRS can achieve perioperative outcomes comparable to those obtained with the established DVSS.